Wednesday, May 7, 2014

Global market for signal transduction therapies/inhibitors to reach $2.2 billion by 2018

Significant developments have come about in both the understanding of the complexity of signal transduction pathways such as JAK and PI3K over the past couple of years. At the same time, much progress has occurred in the isolation of target specific therapies/inhibitors for the abnormal signals within those pathways. Increasing R&D spending, growing rates of cancer and inflammatory diseases, and improving access to healthcare will drive tremendous growth in this market for the foreseeable future.

BCC Research provides an in-depth analysis of the global market for signal transduction therapies/inhibitors (JAK and PI3K) through its report, JAK and PI3K Signaling Pathway Markets. According to the report, this market was valued at nearly $173.5 million in 2012 and $464.5 million in 2013. BCC Research expects the market to grow to $2.2 billion by 2018, and register a five-year compound annual growth rate of 36.8% from 2013 to 2018.

RSS Feeds – Pharmaceuticals
Use this report to:
  • Gain an overview of the global market for signal transduction therapies and inhibitors.
  • Analyze global market trends, with data from 2012 and 2013, and projections of CAGRs through 2018.
  • Evaluate information on approved products such as Ruxolitnib, as well as others in devlopment.
  • Discuss the regulatory environment which is impacting development.
  • Review company profiles of major players in the industry.
To order your copy of this report (or any of its chapters) or to download the complimentary introduction chapter, click here.

No comments:

Post a Comment

Bookmark and Share